Yield10 Bioscience EBIT

Yield10 Bioscience (YTEN) currently reports a EBIT of $-13M as of June 2024. That compares with $-14M in the prior-year period — up 10.1% year over year. That is below the Consumer Discretionary sector average of $150B. Use the charts on this page to explore Yield10 Bioscience's EBIT history and peer comparisons.

Yield10 Bioscience's EBIT increased from $-14M to $-13M — a 10.1% year-over-year increase (period ending June 2024). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Yield10 Bioscience's EBIT of $-13M is lower than the Consumer Discretionary sector average of $150B. That is roughly 100.0% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

Yield10 Bioscience reported $-13M in EBIT as of June 2024. That compares with $-14M in the prior-year period — up 10.1% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current EBIT of $-13M, then check the historical chart for trend and the peer comparison chart for relative positioning. The Consumer Discretionary average is $150B. From there, open related valuation or income-statement pages for Yield10 Bioscience, and consider following YTEN for alerts when major investors trade the stock.